Treatment of autoimmune hemolytic anemias

Current Opinion in Hematology

Volumn 8, Issue 6, 2001, Pages 411-416

  Petz, Lawrence D ^a  

^a StemCyte   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; COLD AGGLUTININ; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DANAZOL; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RITUXIMAB;

AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG INDUCED DISEASE; HEMOLYSIS; HUMAN; PLASMAPHERESIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REMISSION; REVIEW; SPLENECTOMY; STEM CELL; TARGET CELL;

ADRENAL CORTEX HORMONES; AGGLUTININS; ANEMIA, HEMOLYTIC, AUTOIMMUNE; AUTOANTIBODIES; CRYOGLOBULINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; PRACTICE GUIDELINES; SPLENECTOMY; TEMPERATURE;

EID: 0034764789     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200111000-00016     Document Type: Review

References (60)

1. Autoimmune hemolytic anemia
2. Autoimmune hemolytic anemia
3. Autoimmune hemolytic anemia: Current concepts
4. The risks of systemic corticosteroid use
5. Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates
6. Systemic corticosteroid therapy: Side effects and their management
7. Adverse effects of corticosteroids
8. NSAIDs/corticosteroids: Primum non nocere
9. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis
10. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease
11. Splenectomy in the treatment of hemolytic anemia
12. Overwhelming postsplenectomy infection
13. Prevention and management of overwhelming post-splenectomy infection: An update
14. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis
15. Severe late postsplenectomy infection
16. Infection associated with asplenia: Risks, mechanisms, and prevention
17. Late septic complications in adults following splenectomy for trauma: A prospective analysis in 144 patients
18. Overwhelming postsplenectomy infection still a problem
19. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen
20. Long term management after splenectomy
21. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence
22. Autoimmune hemolytic anemia
23. Long-term salvage treatment by cyclosporin in refractory autoimmune hematological disorders
24. Cyclosporin in steroid-resistant autoimmune haemolytic anaemia
25. Control of steroid-resistant autoimmune haemolytic anaemia by cyclosporine
26. Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone
27. Complete remission of refractory anemia following a single high dose of cyclophosphamide
28. Fatal autoimmune hemolytic anemia in a child due to warm-reactive immunoglobulin M antibody
29. Chronic autoimmune hemolytic anemia in children: A report of four patients
30. Rituxan in the treatment of autoimmune hemolytic anemia (AIHA)
31. Treatment with anti-CD20 antibodies of patients with autoimmune thrombocytopenia with or without hemolytic anemia; worsening in hemoglobin level
32. Rituximab, cyclophosphamide and decadron combination is highly effective in auto-immune hemolytic anemia associated with chronic lymphocytic leukemia
33. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: A report of three cases
34. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: A benefit-risk update
35. Rituximab: An innovative therapy for non-Hodgkin's lymphoma
36. Efficacy of danazol in hematologic disorders
37. Danazol in autoimmune haemolytic anaemia
38. Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' syndrome
39. Danazol therapy in patients with immune cytopenias
40. Danazol for treatment of refractory autoimmune hemolytic anaemia
41. Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus
42. Severe autoimmune hemolytic anemia with cold agglutinin and sclerodermic features: Favorable response to danazol
43. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: Results in 73 patients
44. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin
45. Therapeutic apheresis
46. Therapeutic apheresis in hematological and oncological diseases
47. Therapeutic apheresis in autoimmune and rheumatic diseases
48. Management of autoimmune disorders
49. Management of hematological disorders and cancer
50. Low-titer cold-hemagglutinin disease: Mechanism of hemolysis and response to corticosteroids
51. Cold hemagglutinin disease associated with IgG cold-reactive antibody
52. Severe low-titer cold-hemagglutinin disease responsive to steroid pulse therapy
53. Immune haemolytic anaemias
54. Cold agglutinin hemolysis responding to fludarabine therapy
55. Rituxan (Rituximab) therapy for chronic cold agglutinin disease
56. Rituximab: A very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma
57. Remission of severe cold agglutinin disease after Rituximab therapy
58. Paraproteinemias
59. Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders